हानि के कारण उड़ीसा में यूरिया की उपलब्धि थोड़ी प्रभावित हुई थी। तथापि, कमी को आयातों से पूरा किया जा रहा है।

सिंगल सुपर फास्फेट की उपलब्धि इस क्षेत्र में उत्पादन में बाधा के कारण प्रभावित हुई है। सिंगल सुपर फास्फेट की कम आपूर्ति के कारण प्रभावित राज्य सामान्यतः मध्य प्रदेश, महाराष्ट्र, उड़ीसा, पश्चिम बंगाल और उत्तर प्रदेश हैं। प्रभावित राज्यों में फास्फेट की जरूरत को पूरा करने के लिये आयातित डी ए पी उर्वरकों की आपूर्तियां कर दी गयी हैं।

(घ) इस समय डाई अमोनियम फास्फेट, यूरिया, सिंगल सुपर फास्फेट, म्यूरिएट आफ पोटाश एवं काम्पलैक्सों की तरह के नियंत्रित उर्वरक सभी किसानों को रियायती दरों पर उपलब्ध कराये जा रहे हैं।

Nitric Acid Plant

3083. SHRI SATISH PRADHAN: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that RCF (Rashtriya Chemicals and Fertilizer) is operating Nitric Acid Plant without the catchment gauze resulting in enormous loss of platinum Rhodium running into crores of rupees;

(b) if so, the details thereof;

(c) the reasons for discontinuation of use of catchment gauze required for operation of Nitric Acid Plant; and

(d) whether any irregularity is observed in supply of catchment gauze and if so, the details thereof including action taken in the matter?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (d) From 7th January, 1992, Rashtriya Chemicals & Fertilizers Ltd. (RCF) are not using the catchment gauze in its nitric acid plant of 750 tonnes per day capacity. RCF is taking necessary action to avoid loss in this regard.

The contract with the supplier of the catchment gauze has been terminated by RCF consequent upon certain irregularties, including production of allegedly false test reports regarding the quality and the metal content in the catchment guaze. The CBI has been requested to investigate the case.

Recoveries from M/s. Hoechst and Carews

3084. MAULANA OBAIDULLAH KHAN AZMI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that large recoveries amounting to lakhs of rupees have to be made from M/s. Hoechst (India) Limited and M/s. Carews Co. into D.P.E.A.;

(b) if so, what are the reasons for the accumulation of such a huge amount to be recovered from these companies;

(c) whether the timely payment were not made by M/s. Hoechst (India) Ltd. and M/s. Carews Co.;

(d) if so, what action has been taken against the company and the persons responsible for it; and

(e) what measures Government have taken or proposed to take to recover the amount from these companies?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (e) The liability into Drugs Price Equilisation Account against M/s. Hoechst and M/s. Carews has been tentatively worked out to Rs. 77.81 and 7.10 crores (including overcharging during the currency of DPCO, 1987) respectively. The liability of M/s. Hoechst have been accrued due to over-charging of prices of bulk drugs and formulations fixed in 1980-81 under DPCO, 1979. The company went to Court and got stay against the prices fixed by Government. The Supreme Court give the decision in Government's favour in April/May, 1987. The tentative liability of M/s. Hoechst was assessed by special team as Rs. 4.58 crores

which was revised to Rs 77.81 crores in 1990, against which M/s. Hoechst filed Writ Petition in Bombay Court. The Bombay Court framed a time bound schedule for finalising the liability. giving the hearing to the company and passing a final speaking order. The company has been given last and final opportunity to submit the requisite data. In case full data is not given by the company whatever data becomes available to the Government from whichever source, will be made use of to supplement the company's data. After the liability has been tentatively determined in this way. the company will be givtn a hearing in accordance with the Bombay High Court's Order and a Speaking Order will be passed hereafter, M/s. Hoechst has made a payment of Rs. 3.12 crores against their liabilities.

As regards M/s. Carews, it came to notice of Government that this company was manufacturing and marketing Combiflam tablets through M/s. Roussel Pharmaceutical without price approval under DPCO, 1979 as will as DPCO, 1987. It was noted that the company was overcharging in the price of Combiflam tablets between the period November, 1986 to August, 1989. A tentative liability of 7.11 crores has been calculated aaginst this company for the period November, 1986 to December, 1988. This amount was communicated to the company with the advice to deposit the same with the Government and details pertaining to the remaining period were also called for to work out the total liability. The company filed 3 Writ Petitions in Calcutta High Court, which are, at present, pending in the Calcutta High Court.

Recoveries to be made from M/s. Merck India Ltd.

3085. SHRI SANTOSH KUMAR SAHU: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that M/s. E. Merck India Ltd. is followed as leader price for Ibuprofen 400 Mg and Paracotamol 325 Mg. combination;

(b) whether any demand has been raised on the company for recovering of amount overcharged from November, 1986 to December, 1988; and

(c) if not, the reasons to which Government have not initiated any proceedings against the company?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) No, Sir.

(b) No, Sir.

(c) *Prima facie*, there appears to be no case of overcharging against the company. However, Government is yet to take a final view in the matter.

Furnishing of details of imports by Multinational Companies

3086. MISS SAROJ KHAPARDE: Will the PRIME MINISTER be pleased to state:

(a) whether Government have directed the Indian offshots of Multinational companies to furnish the details of the products they import from their overseas parent companies and associate companies; and

(b) if so, what are the details in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) Attention of drug companies has been invited through industry associations to para 6.7 of the "Measures for Rationalisation Quality Control and Growth of Pharmaceutical Industry in India" announced by the Government in December, 1986 requesting them to furnish the following details:—

1. List of bulk drugs manufactured by the company.

2. Details of intermediates and other raw materials imported by the company from their principals or their associated companies for manufacture of each bulk drug since January 1987, yearwise,